Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study.

Antimicrobial Agents and Chemotherapy
Aikaterini SpyridakiEvangelos J Giamarellos-Bourboulis

Abstract

One recent, double-blind, randomized clinical trial with 200 patients showed that clarithromycin administered intravenously for 3 days in patients with ventilator-associated pneumonia (VAP) accelerated the resolution of pneumonia and decreased the risk of death from septic shock and multiple organ dysfunctions (MODS). The present study focused on the effect of clarithromycin on markers of inflammation in these patients. Blood was drawn immediately before the administration of the allocated treatment and on six consecutive days after the start of treatment. The concentrations of circulating markers were measured. Monocytes and neutrophils were isolated for immunophenotyping analysis and for cytokine stimulation. The ratio of serum interleukin-10 (IL-10) to serum tumor necrosis factor alpha (TNF-α) was decreased in the clarithromycin group compared with the results in the placebo group. Apoptosis of monocytes was significantly increased on day 4 in the clarithromycin group compared with the rate of apoptosis in the placebo group. On the same day, the expression of CD86 was increased and the ratio of soluble CD40 ligand (sCD40L) to CD86 in serum was unchanged. The release of TNF-α, IL-6, and soluble triggering receptor expressed o...Continue Reading

References

Aug 11, 2001·Intensive Care Medicine·J J SáenzI Gaminde
Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jean-Louis VincentMarc-Jacques Dubois
Nov 24, 2004·The Journal of Experimental Medicine·Sébastien GibotGilbert C Faure
May 16, 2006·Critical Care : the Official Journal of the Critical Care Forum·Evangelos J Giamarellos-BourboulisHelen Giamarellou
Apr 26, 2007·The American Journal of Pathology·Daniel G Remick
Nov 22, 2007·Lancet·Kenneth HillUNKNOWN Monitoring of Vital Events (MoVE)
Jan 15, 2008·Immunology Letters·Anja S Tessarz, Adelheid Cerwenka
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Evangelos J Giamarellos-BourboulisHelen Giamarellou
Sep 20, 2008·Nature Reviews. Immunology·Daniel RittirschPeter A Ward
Oct 24, 2008·Clinical and Vaccine Immunology : CVI·Anna SinistroAlberto Bergamini
Dec 7, 2010·International Journal of Antimicrobial Agents·Evangelos J Giamarellos-Bourboulis
Jan 20, 2011·Critical Care : the Official Journal of the Critical Care Forum·Evangelos J Giamarellos-BourboulisMihai G Netea
Nov 5, 2011·BMC Infectious Diseases·Thekla PoukoulidouUNKNOWN Hellenic Sepsis Study Group

❮ Previous
Next ❯

Citations

May 15, 2013·International Journal of Antimicrobial Agents·Evangelos J Giamarellos-Bourboulis
Jun 12, 2013·Immunology Letters·Ioannis KritselisEvangelos J Giamarellos-Bourboulis
Mar 26, 2013·Current Opinion in Pulmonary Medicine·François BarbierLila Bouadma
Jan 18, 2013·Critical Care : the Official Journal of the Critical Care Forum·Chryssoula ToufekoulaEvangelos J Giamarellos-Bourboulis
Mar 1, 2013·Immunotherapy·Evangelos J Giamarellos-Bourboulis
Dec 3, 2013·The Journal of Antimicrobial Chemotherapy·Evangelos J Giamarellos-BourboulisApostolos Armaganidis
Jul 12, 2012·Expert Opinion on Emerging Drugs·Antigone Kotsaki, Evangelos J Giamarellos-Bourboulis
Jan 25, 2016·Journal of Critical Care·Majid AfsharEllen L Burnham
Sep 17, 2015·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·JoonHo LeeBo Hyun Yoon
Oct 9, 2015·Current Infectious Disease Reports·Alexandra McFarlane, Wendy Sligl
Mar 19, 2014·Pharmacology & Therapeutics·Michael J ParnhamRobin Vos
Mar 4, 2014·Clinical Genetics·E Christaki, E J Giamarellos-Bourboulis
Apr 8, 2015·Respiratory Research·María-José LorenzoRosario Menéndez
Apr 1, 2014·The Journal of Urology·Matthew P KatsarisMichael Chrisofos
Apr 14, 2016·Chest·Hollis R O'NealGeorge H Karam
Apr 6, 2016·Antimicrobial Agents and Chemotherapy·Thomas TsaganosEvangelos J Giamarellos-Bourboulis
Jan 19, 2019·The Cochrane Database of Systematic Reviews·Malene Plejdrup HansenChris B Del Mar
May 8, 2020·International Reviews of Immunology·Pedro Henrique Dos Santos DantasHelioswilton Sales-Campos
Jan 14, 2020·Pharmacology & Therapeutics·Folkert SteinhagenChristian Bode
Apr 3, 2021·Frontiers in Microbiology·Anne-Gaëlle LeroyLise Crémet
Oct 8, 2021·European Respiratory Review : an Official Journal of the European Respiratory Society·Andrea SauerChristian Bode

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Evangelos J Giamarellos-BourboulisHelen Giamarellou
JAMA : the Journal of the American Medical Association
Jonathan S BoomerRichard S Hotchkiss
American Journal of Respiratory Cell and Molecular Biology
Magali MeyerTeresinha Leal
© 2021 Meta ULC. All rights reserved